Lantheus Holdings, Inc. is 4.0x more valuable than Intellia Therapeutics, Inc. by market capitalization ($6.80 B vs $1.69 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NTLA | LNTH |
|---|---|---|
| Market cap | $1.69 B | $6.80 B |
| US-listed rank | #2235 | #1188 |
| Revenue (latest FY) | $67.67M | $1.54B |
| Net income (latest FY) | -$412.69M | $233.56M |
| Net margin | -609.9% | 15.2% |
| P/E (trailing FY) | - | 29.1 |
| SEC filings | 687 | 1,079 |
Lantheus Holdings, Inc. is 4.0x more valuable than Intellia Therapeutics, Inc. by market capitalization ($6.80 B vs $1.69 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while Lantheus Holdings, Inc. reported $1.54B.
Full pages: Intellia Therapeutics, Inc. and Lantheus Holdings, Inc., or browse the full rankings.